Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)

EVplusEV (75.25) Submitted: 7/6/2012 8:47:51 PM : Start Price: $1.61 ASTX Score: +95.63

I like ASTX as a speculative play. It is one of the rare small BioTechs that is actually profitable. It has several drugs in the pipeline and one (Dacogen) already approved and selling. It sold off a few months ago when the FDA did not approve Dacogen for alternative treatment but is now oversold considering it's pipeline, fantastic balance sheet with zero debt, and recent royalty from JNJ for hitting targets on a joint venture. A lot to like here for a spec play.